- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Kuros Biosciences
Market Cap: CHF 928.9m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 23.54
7D
15.6%
1Y
-21.6%
Basilea Pharmaceutica
Market Cap: CHF 647.1m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 52.20
7D
-0.2%
1Y
-10.0%
Tecan Group
Market Cap: CHF 2.3b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 186.90
7D
4.1%
1Y
15.4%
Roche Holding
Market Cap: CHF 282.2b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 353.40
7D
1.1%
1Y
37.5%